Brief: Aadi Bioscience Provides Precision1 Trial And Corporate Updates

Whitehawk Therapeutics

20/08/2024 22:52

Aug 20 (Reuters) - Aadi Bioscience Inc  AADI.O :
    * AADI BIOSCIENCE PROVIDES PRECISION1 TRIAL AND CORPORATE
UPDATES
    * AADI BIOSCIENCE INC: PRECISION1 TUMOR-AGNOSTIC TRIAL
UNLIKELY TO
MEET REGULATORY THRESHOLD
    * AADI BIOSCIENCE INC: TO FURTHER PRESERVE CASH POSITION,
AADI
WILL ADJUST ONGOING PHASE 2 TRIALS AND REDUCE RESEARCH AND
DEVELOPMENT HEADCOUNT BY 80%
    * AADI BIOSCIENCE INC: EXTENDING CASH RUNWAY INTO AT LEAST
2H 2026
    * AADI BIOSCIENCE INC: AADI WILL FOCUS ON FYARRO(®)
COMMERCIAL
BUSINESS FOR ITS APPROVED INDICATION
    * AADI BIOSCIENCE: TO FURTHER PRESERVE CASH, WILL PAUSE NEW
ENROLLMENT, CONTINUE DOSING ENROLLED PATIENTS, IN ONGOING PHASE
2 TRIALS OF NAB-SIROLIMUS

Source text for Eikon:  ID:nPnbhLQJba 
Further company coverage:  AADI.O 

 ((Reuters.Briefs@thomsonreuters.com;))